Both MERTK and AXL are expressed in a wide variety of human cancers, including NSCLC [51], melanoma [95], leukemia [96,97], breast [98], colon [99], liver [100], gastric [101], prostate [102,103], ovarian [104], and brain cancers [105,106], where they promote tumor cell survival and/or proliferation and contribute to oncogenesis. Here, AXL is linked to non-small cell lung carcinoma.